The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal ...

Both trials met their primary endpoints, indicating a significant improvement in patients treated with the drug.

GSK announces positive phase III results from ANCHOR trials for depemokimab in chronic rhinosinusitis with nasal polyps: London, UK Tuesday, October 15, 2024, 10:00 Hrs [IST] GSK ...

The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.

UK pharma major GSK today announced positive headline results from two Phase III clinical trials, ANCHOR-1 and ANCHOR-2, ...

GSK plc has announced positive results from its Phase III ANCHOR trials for depemokimab, a biologic treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). The trials demonstrated a ...

GSK plc has announced positive results from its Phase III ANCHOR trials for depemokimab, a biologic treatment for chronic ...

GSK's depemokimab met key endpoints in phase 3 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), showing promise ...

Depemokimab has already shown its potential as a therapy for severe asthma in two other phase 3 trials – SWIFT-1 and SWIFT-2 ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been ...

GSK said that both the Anchor-1 and Anchor-2 trials met their co-primary endpoints of a change from baseline in total endoscopic nasal polyp score after 52 weeks, as well as a change in mean nasal ...